General | |
---|---|
Symbol | 125I |
Names | iodine-125, 125I, I-125, radioiodine |
Protons (Z) | 53 |
Neutrons (N) | 72 |
Nuclide data | |
Natural abundance | synth |
Half-life (t1/2) | 59.392±0.008 d [1] |
Isotope mass | 124.9046306(15) [2] Da |
Parent isotopes | parent_mass125Xe |
Decay products | decay_mass125Te |
Decay modes | |
Decay mode | Decay energy (MeV) |
electron capture | 0.035 (35 keV) |
Isotopes of iodine Complete table of nuclides |
Iodine-125 (125I) is a radioisotope of iodine which has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumors. It is the second longest-lived radioisotope of iodine, after iodine-129.
Its half-life is 59.392 days and it decays by electron capture to an excited state of tellurium-125. This state is not the metastable 125mTe, but rather a lower energy state that decays immediately by gamma decay with a maximum energy of 35 keV. Some of the excess energy of the excited 125Te may be internally converted ejected electrons (also at 35 keV), or to x-rays (from electron bremsstrahlung), and also a total of 21 Auger electrons, which are produced at the low energies of 50 to 500 electron volts. [3] Eventually, stable ground state 125Te is produced as the final decay product.
In medical applications, the internal conversion and Auger electrons cause little damage outside the cell which contains the isotope atom. The X-rays and gamma rays are of low enough energy to deliver a higher radiation dose selectively to nearby tissues, in "permanent" brachytherapy where the isotope capsules are left in place (125I competes with palladium-103 in such uses). [4]
Because of its relatively long half-life and emission of low-energy photons which can be detected by gamma-counter crystal detectors, 125I is a preferred isotope for tagging antibodies in radioimmunoassay and other gamma-counting procedures involving proteins outside the body. The same properties of the isotope make it useful for brachytherapy, and for certain nuclear medicine scanning procedures, in which it is attached to proteins (albumin or fibrinogen), and where a half-life longer than that provided by 123I is required for diagnostic or lab tests lasting several days.
Iodine-125 can be used in scanning/imaging the thyroid, but iodine-123 is preferred for this purpose, due to better radiation penetration and shorter half-life (13 hours). 125I is useful for glomerular filtration rate (GFR) testing in the diagnosis or monitoring of patients with kidney disease. Iodine-125 is used therapeutically in brachytherapy treatments of tumors. For radiotherapy ablation of tissues that absorb iodine (such as the thyroid), or that absorb an iodine-containing radiopharmaceutical, the beta-emitter iodine-131 is the preferred isotope.
When studying plant immunity, 125I is used as the radiolabel in tracking ligands to determine which plant pattern recognition receptors (PRRs) they bind to. [5]
125I is produced by the electron capture decay of 125Xe, which is an artificial isotope of xenon, itself created by neutron capture of near-stable 124Xe (it undergoes double electron capture with a half life orders of magnitude larger than the age of the universe), which makes up around 0.1% of naturally occurring xenon. Because of the artificial production route of 125I and its short half-life, its natural abundance on Earth is effectively zero.
125I is a reactor-produced radionuclide and is available in large quantities. Its production involves the two following nuclear reactions:
The irradiation target is the primordial nuclide 124Xe, which is the target isotope for making 125I by neutron capture. It is loaded into irradiation capsules of the zirconium alloy zircaloy-2 (a corrosion resisting alloy transparent to neutrons) to a pressure of about 100 bar (~ 100 atm). Upon irradiation with slow neutrons in a nuclear reactor, several radioisotopes of xenon are produced. However, only the decay of 125Xe leads to a radioiodine: 125I. The other xenon radioisotopes decay either to stable xenon, or to various caesium isotopes, some of them radioactive (a.o., the long-lived 135Cs (t½ = 1.33 Ma) and 137Cs (t½ = 30 a)).
Long irradiation times are disadvantageous. Iodine-125 itself has a neutron capture cross section of 900 barns, and consequently during a long irradiation, part of the 125I formed will be converted to 126I, a beta-emitter and positron-emitter with a half-life of 12.93 days [1] , which is not medically useful. In practice, the most useful irradiation time in the reactor amounts to a few days. Thereafter, the irradiated gas is allowed to decay for three or four days to eliminate short-lived unwanted radioisotopes, and to allow the newly produced xenon-125 (t½ = 17 hours) to decay to iodine-125.
To isolate radio-iodine, the irradiated capsule is first cooled at low temperature (to condense the free iodine gas onto the capsule inner wall) and the remaining Xe gas is vented in a controlled way and recovered for further use. The inner walls of the capsule are then rinsed with a dilute NaOH solution to collect iodine as soluble iodide (I−) and hypoiodite (IO−), according to the standard disproportionation reaction of halogens in alkaline solution. Any caesium atom present immediately oxidizes and passes into the water as Cs+. In order to eliminate any long-lived 135Cs and 137Cs which may be present in small amounts, the solution is passed through a cation-exchange column, which exchanges Cs+ for another non-radioactive cation (e.g., Na+). The radioiodine (as anion I− or IO−) remains in solution as a mixture iodide/hypoiodite.
Iodine-125 is commercially available in dilute NaOH solution as 125I-iodide (or the hypohalite sodium hypoiodite, NaIO). The radioactive concentration lies at 4 to 11 GBq/mL and the specific radioactivity is > 75 GBq/μmol(7.5 × 1016 Bq/mol). The chemical and radiochemical purity is high. The radionuclidic purity is also high; some 126I (t1/2 = 12.93 d) [1] is unavoidable due to the neutron capture noted above. The 126I tolerable content (which is set by the unwanted isotope interfering with dose calculations in brachytherapy) lies at about 0.2 atom % (atom fraction) of the total iodine (the rest being 125I).
As of October 2019, there were two producers of iodine-125, the McMaster Nuclear Reactor in Hamilton, Ontario, Canada; and a VVR-SM research reactor in Uzbekistan. [6] The McMaster reactor is presently the largest producer of iodine-125, producing approximately 60 per cent of the global supply in 2018; [7] with the remaining global supply produced at the reactor based in Uzbekistan. Annually, the McMaster reactor produces enough iodine-125 to treat approximately 70,000 patients. [8]
In November 2019, the research reactor in Uzbekistan shut down temporarily in order to facilitate repairs. The temporary shutdown threatened the global supply of the radioisotope by leaving the McMaster reactor as the sole producer of iodine-125 during the period. [6] [8]
Prior to 2018, the National Research Universal (NRU) reactor at Chalk River Laboratories in Deep River, Ontario, was one of three reactors to produce iodine-125. [9] However, on March 31, 2018, the NRU reactor was permanently shut down ahead of its scheduled decommissioning in 2028, as a result of a government order. [10] [11] The Russian nuclear reactor equipped to produce iodine-125, was offline as of December 2019. [6]
The detailed decay mechanism to form the stable daughter nuclide tellurium-125 is a multi-step process that begins with electron capture. This is followed by a cascade of electron relaxation as the core electron hole moves toward the valence orbitals. The cascade involves many Auger transitions, each of which cause the atom to become increasingly ionized. The electron capture produces a tellurium-125 nucleus in an excited state with a half-life of 1.6 ns, which undergoes gamma decay emitting a gamma photon or an internal conversion electron at 35.5 keV. A second electron relaxation cascade follows the gamma decay before the nuclide comes to rest. Throughout the entire process an average of 13.3 electrons are emitted (10.3 of which are Auger electrons), most with energies less than 400 eV (79% of yield). [12] The internal conversion and Auger electrons from the radioisotope have been found in one study to do little cellular damage, unless the radionuclide is directly incorporated chemically into cellular DNA, which is not the case for present radiopharmaceuticals which use 125I as the radioactive label nuclide. [13]
As with other radioisotopes of iodine, accidental iodine-125 uptake in the body (mostly by the thyroid gland) can be blocked by the prompt administration of stable iodine-127 in the form of an iodide salt. [14] [15] Potassium iodide (KI) is typically used for this purpose. [16]
However, unjustified self-medicated preventive administration of stable KI is not recommended in order to avoid disturbing the normal thyroid function. Such a treatment must be carefully dosed and requires an appropriate KI amount prescribed by a specialised physician.
Neutron activation analysis (NAA) is a nuclear process used for determining the concentrations of elements in many materials. NAA allows discrete sampling of elements as it disregards the chemical form of a sample, and focuses solely on atomic nuclei. The method is based on neutron activation and thus requires a neutron source. The sample is bombarded with neutrons, causing its constituent elements to form radioactive isotopes. The radioactive emissions and radioactive decay paths for each element have long been studied and determined. Using this information, it is possible to study spectra of the emissions of the radioactive sample, and determine the concentrations of the various elements within it. A particular advantage of this technique is that it does not destroy the sample, and thus has been used for the analysis of works of art and historical artifacts. NAA can also be used to determine the activity of a radioactive sample.
A radionuclide (radioactive nuclide, radioisotope or radioactive isotope) is a nuclide that has excess numbers of either neutrons or protons, giving it excess nuclear energy, and making it unstable. This excess energy can be used in one of three ways: emitted from the nucleus as gamma radiation; transferred to one of its electrons to release it as a conversion electron; or used to create and emit a new particle (alpha particle or beta particle) from the nucleus. During those processes, the radionuclide is said to undergo radioactive decay. These emissions are considered ionizing radiation because they are energetic enough to liberate an electron from another atom. The radioactive decay can produce a stable nuclide or will sometimes produce a new unstable radionuclide which may undergo further decay. Radioactive decay is a random process at the level of single atoms: it is impossible to predict when one particular atom will decay. However, for a collection of atoms of a single nuclide the decay rate, and thus the half-life (t1/2) for that collection, can be calculated from their measured decay constants. The range of the half-lives of radioactive atoms has no known limits and spans a time range of over 55 orders of magnitude.
A beta particle, also called beta ray or beta radiation, is a high-energy, high-speed electron or positron emitted by the radioactive decay of an atomic nucleus, known as beta decay. There are two forms of beta decay, β− decay and β+ decay, which produce electrons and positrons, respectively.
A synthetic radioisotope is a radionuclide that is not found in nature: no natural process or mechanism exists which produces it, or it is so unstable that it decays away in a very short period of time. Frédéric Joliot-Curie and Irène Joliot-Curie were the first to produce a synthetic radioisotope in the 20th century. Examples include technetium-99 and promethium-146. Many of these are found in, and harvested from, spent nuclear fuel assemblies. Some must be manufactured in particle accelerators.
A radioactive tracer, radiotracer, or radioactive label is a synthetic derivative of a natural compound in which one or more atoms have been replaced by a radionuclide. By virtue of its radioactive decay, it can be used to explore the mechanism of chemical reactions by tracing the path that the radioisotope follows from reactants to products. Radiolabeling or radiotracing is thus the radioactive form of isotopic labeling. In biological contexts, experiments that use radioisotope tracers are sometimes called radioisotope feeding experiments.
Nuclear fission products are the atomic fragments left after a large atomic nucleus undergoes nuclear fission. Typically, a large nucleus like that of uranium fissions by splitting into two smaller nuclei, along with a few neutrons, the release of heat energy, and gamma rays. The two smaller nuclei are the fission products..
Neutron activation is the process in which neutron radiation induces radioactivity in materials, and occurs when atomic nuclei capture free neutrons, becoming heavier and entering excited states. The excited nucleus decays immediately by emitting gamma rays, or particles such as beta particles, alpha particles, fission products, and neutrons. Thus, the process of neutron capture, even after any intermediate decay, often results in the formation of an unstable activation product. Such radioactive nuclei can exhibit half-lives ranging from small fractions of a second to many years.
Iodine-131 is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production. It also plays a major role as a radioactive isotope present in nuclear fission products, and was a significant contributor to the health hazards from open-air atomic bomb testing in the 1950s, and from the Chernobyl disaster, as well as being a large fraction of the contamination hazard in the first weeks in the Fukushima nuclear crisis. This is because 131I is a major fission product of uranium and plutonium, comprising nearly 3% of the total products of fission. See fission product yield for a comparison with other radioactive fission products. 131I is also a major fission product of uranium-233, produced from thorium.
Neutron capture is a nuclear reaction in which an atomic nucleus and one or more neutrons collide and merge to form a heavier nucleus. Since neutrons have no electric charge, they can enter a nucleus more easily than positively charged protons, which are repelled electrostatically.
There are 40 known isotopes of iodine (53I) from 108I to 147I; all undergo radioactive decay except 127I, which is stable. Iodine is thus a monoisotopic element.
Caesium (55Cs) has 41 known isotopes, the atomic masses of these isotopes range from 112 to 152. Only one isotope, 133Cs, is stable. The longest-lived radioisotopes are 135Cs with a half-life of 1.33 million years, 137
Cs
with a half-life of 30.1671 years and 134Cs with a half-life of 2.0652 years. All other isotopes have half-lives less than 2 weeks, most under an hour.
Naturally occurring zirconium (40Zr) is composed of four stable isotopes (of which one may in the future be found radioactive), and one very long-lived radioisotope (96Zr), a primordial nuclide that decays via double beta decay with an observed half-life of 2.0×1019 years; it can also undergo single beta decay, which is not yet observed, but the theoretically predicted value of t1/2 is 2.4×1020 years. The second most stable radioisotope is 93Zr, which has a half-life of 1.53 million years. Thirty other radioisotopes have been observed. All have half-lives less than a day except for 95Zr (64.02 days), 88Zr (83.4 days), and 89Zr (78.41 hours). The primary decay mode is electron capture for isotopes lighter than 92Zr, and the primary mode for heavier isotopes is beta decay.
Natural nitrogen (7N) consists of two stable isotopes: the vast majority (99.6%) of naturally occurring nitrogen is nitrogen-14, with the remainder being nitrogen-15. Thirteen radioisotopes are also known, with atomic masses ranging from 9 to 23, along with three nuclear isomers. All of these radioisotopes are short-lived, the longest-lived being nitrogen-13 with a half-life of 9.965(4) min. All of the others have half-lives below 7.15 seconds, with most of these being below 620 milliseconds. Most of the isotopes with atomic mass numbers below 14 decay to isotopes of carbon, while most of the isotopes with masses above 15 decay to isotopes of oxygen. The shortest-lived known isotope is nitrogen-10, with a half-life of 143(36) yoctoseconds, though the half-life of nitrogen-9 has not been measured exactly.
Plutonium (94Pu) is an artificial element, except for trace quantities resulting from neutron capture by uranium, and thus a standard atomic weight cannot be given. Like all artificial elements, it has no stable isotopes. It was synthesized long before being found in nature, the first isotope synthesized being plutonium-238 in 1940. Twenty plutonium radioisotopes have been characterized. The most stable are plutonium-244 with a half-life of 80.8 million years; plutonium-242 with a half-life of 373,300 years; and plutonium-239 with a half-life of 24,110 years; and plutonium-240 with a half-life of 6,560 years. This element also has eight meta states; all have half-lives of less than one second.
Americium (95Am) is an artificial element, and thus a standard atomic weight cannot be given. Like all artificial elements, it has no known stable isotopes. The first isotope to be synthesized was 241Am in 1944. The artificial element decays by ejecting alpha particles. Americium has an atomic number of 95. Despite 243
Am being an order of magnitude longer lived than 241
Am, the former is harder to obtain than the latter as more of it is present in spent nuclear fuel.
Radionuclides which emit gamma radiation are valuable in a range of different industrial, scientific and medical technologies. This article lists some common gamma-emitting radionuclides of technological importance, and their properties.
This page discusses each of the main elements in the mixture of fission products produced by nuclear fission of the common nuclear fuels uranium and plutonium. The isotopes are listed by element, in order by atomic number.
Iodine-123 (123I) is a radioactive isotope of iodine used in nuclear medicine imaging, including single-photon emission computed tomography (SPECT) or SPECT/CT exams. The isotope's half-life is 13.2232 hours; the decay by electron capture to tellurium-123 emits gamma radiation with a predominant energy of 159 keV. In medical applications, the radiation is detected by a gamma camera. The isotope is typically applied as iodide-123, the anionic form.
Long-lived fission products (LLFPs) are radioactive materials with a long half-life produced by nuclear fission of uranium and plutonium. Because of their persistent radiotoxicity, it is necessary to isolate them from humans and the biosphere and to confine them in nuclear waste repositories for geological periods of time. The focus of this article is radioisotopes (radionuclides) generated by fission reactors.
Radiopharmaceuticals, or medicinal radiocompounds, are a group of pharmaceutical drugs containing radioactive isotopes. Radiopharmaceuticals can be used as diagnostic and therapeutic agents. Radiopharmaceuticals emit radiation themselves, which is different from contrast media which absorb or alter external electromagnetism or ultrasound. Radiopharmacology is the branch of pharmacology that specializes in these agents.